Participated · Equity · Jul 2026

410 Medical develops advanced resuscitation technologies centered on its lead product, the LifeFlow infuser, which received FDA clearance in 2016. LifeFlow is used by more than 500 hospitals and EMS agencies and has been used to treat nearly 80,000 patients experiencing conditions like sepsis and hemorrhagic shock. The company was founded in 2013 and is based in North Carolina. In July 2026 410 Medical raised $12 million in growth financing led by Orlando Health Ventures to scale commercial operations and accelerate LifeFlow adoption. The company is also investing in a next-generation LifeFlow device planned for launch in 2027. The financing was supported by a syndicate of hospital and healthcare investors, reflecting continued commercial momentum.

Participated · Equity · Nov 2024

TailorMed provides an enterprise platform that manages the full lifecycle of patient support programs to reduce cost barriers and improve medication access and adherence. The company has built the nation’s largest Affordability Network, deployed across more than 800 hospitals, 1,300 clinics, and 650 pharmacies. TailorMed integrates directly with manufacturer assistance programs to automate patient support and streamline stakeholder workflows. Having reached an inflection point in its network evolution, the company is expanding into an end-to-end platform to tackle cost, access, and adherence across the medication continuum. The new financing will fund that expansion and broader efforts to create a seamless flow of data and resources across patients, providers, pharmacies, life sciences, and payers. TailorMed frames this work as addressing affordability at the point a prescription is written or dispensed to prevent delayed or skipped treatments. TailorMed Medical provides a technology platform that automates identification of financially at-risk patients and matches and enrolls them in financial resources such as co-pay assistance, replacement drug programs, government subsidies, community and state resources, disease-specific foundations, and programs addressing living expenses. Its platform is designed to reduce out-of-pocket responsibility for patients, helping to eliminate downstream financial hardship and avoidance of care. For health organizations, TailorMed shifts financial assistance from reactive matching or downstream collections to a proactive, point-of-care approach. The company serves physician practices, specialty clinics and health systems, and in 2021 expanded adoption into pharmacies nationwide. TailorMed said it will use the new funding to further expand its reach across health care with innovative financial solutions. Srulik Dvorsky is CEO and co-founder and the company is based in New York City.

Participated · Series E · Sep 2024

Inflammatix is reimagining infectious-disease diagnostics by using proprietary host-response biomarkers and machine learning to measure gene expression patterns from a finger-stick blood sample. Its sample-to-answer Myrna instrument platform delivers results in under 30 minutes and is being paired with the ViraBac EZ test, which tells physicians whether an infection is bacterial or viral so they can prescribe antibiotics appropriately. The company’s initial focus areas are acute infections and sepsis, large markets where faster, more precise information can improve outcomes and curb antibiotic resistance. Inflammatix’s technology aims to reduce the estimated 30 % of antibiotics that are inappropriately prescribed in U.S. outpatient settings each year. Commercialization efforts are currently supported by non-dilutive government funding and venture backing from Khosla Ventures, Northpond Ventures, Stanford StartX Fund, Think.Health Ventures, and OSF Ventures. A BARDA contract worth up to $72 million, if all options are exercised, underpins ongoing product development. The latest tranche of BARDA financing brings additional resources to finalize the testing system and move it toward market launch.

Participated · Equity · Jan 2023

Array Behavioral Care is a Mount Laurel, NJ-based provider of virtual psychiatry and therapy services that delivers telepsychiatry solutions across the continuum of care, from hospital to home. The company supports psychiatrists, therapists, and other clinicians with clinical, operational, administrative, and technical specialists so providers can operate at the top of their licenses and focus on direct patient care. Array has partnered for more than 20 years with hundreds of hospitals, health systems, community healthcare organizations, and payers to expand access and improve outcomes for underserved individuals, facilities, and communities. Today about 90 million Americans can access Array’s services across all 50 states. The company plans to use the new funding to scale in new and existing markets through enhanced service offerings and operations, innovative technology, and expansion of the practice team. Array is led by CEO Geoffrey Boyce and Executive Chief Medical Officer Dr. James Varrell.

Participated · Series B · Jun 2022

Socially Determined provides Social Risk Intelligence through its SocialScape® SaaS platform and advisory services, aggregating data and proprietary analytics to reveal where social risk exists and how it affects health outcomes. The platform is designed for payers, life sciences companies, providers and other stakeholders to reduce healthcare disparities and improve engagement. The company has an expanded partnership with CareFirst BlueCross BlueShield to serve CareFirst’s 3.5 million members through an enterprise-wide deployment of SocialScape. Socially Determined said it has gathered data sets on factors like food insecurity, transportation barriers, and financial strain and built analytics and expertise to standardize SDOH assessment at scale. Headquartered in Washington, D.C., it was recently named by Fierce Healthcare as one of the 15 most promising healthcare companies. The company closed a $26 million Series B and will use proceeds to fund product enhancements, sales and marketing, and R&D focused on further technology and platform automation. Socially Determined builds analytics focused on the science and measurement of social determinants of health (SDOH). Its flagship platform, SocialScape®, quantifies social risk and delivers insights into how SDOH affect utilization, cost, and outcomes. The technology is supported by a team of experts who provide SDOH program evaluation, deep cohort analysis, and guidance to clients. The company helps clients grow lines of business into new geographies and risk arrangements through analytic insights. Socially Determined plans to use the Series A proceeds to continue expanding operations and its business reach. The company was co-founded in 2017 by Trenor Williams, MD, Ryan Bosch, MD, and Anthony Beverina and is based in Washington, DC, with a second office in Blacksburg, VA.